{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:43:30Z","timestamp":1792784610330,"version":"4.5.0"},"reference-count":51,"publisher":"American Chemical Society (ACS)","issue":"20","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"name":"Fukushima Institute for Research, Education and Innovation","award":["JPFR24040302"],"award-info":[{"award-number":["JPFR24040302"]}],"id":[{"id":"https:\/\/ror.org\/01kq2by19","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Fukushima Institute for Research, Education and Innovation","award":["JPFR25040302"],"award-info":[{"award-number":["JPFR25040302"]}],"id":[{"id":"https:\/\/ror.org\/01kq2by19","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22H04924"],"award-info":[{"award-number":["22H04924"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Neurotensin receptor 1 (NTSR1) is overexpressed in various types of cancer and known as a promising target for cancer therapy. Targeted alpha therapy (TAT) using \u03b1-emitting radionuclides with high linear energy transfer is expected to show potent therapeutic efficacy. In this study, we aimed to develop an 211At-labeled NTSR1-TAT agent. To achieve this, [125I]IB-NTS, [125I]IB-DOTA-NTS, and [125I]IB-In-DOTA-NTS were newly designed, synthesized, and evaluated using 125I as a surrogate radionuclide. These 125I-labeled compounds showed high stability in murine plasma and NTSR1-binding affinity. In the biodistribution study, [125I]IB-In-DOTA-NTS demonstrated the most favorable tumor uptake among the three compounds and in vivo NTSR1-specificity. Therefore, [211At]AB-In-DOTA-NTS was synthesized and its utility as an NTSR1-TAT agent was evaluated. [211At]AB-In-DOTA-NTS exhibited dose-dependent antitumor effects without sustained or dose-dependent body weight loss in HT-29 tumor-bearing mice. This study demonstrated that [211At]AB-In-DOTA-NTS is a promising candidate for TAT and represents the first report of an 211At-labeled NTSR1-TAT agent.<\/jats:p>","DOI":"10.1021\/acs.jmedchem.6c00852","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T06:30:04Z","timestamp":1790317804000},"page":"23585-23600","source":"Crossref","is-referenced-by-count":0,"title":["Development of Novel 211At-Labeled Agent for Neurotensin Receptor 1-Targeted \u03b1-Particle Therapy"],"prefix":"10.1021","volume":"69","author":[{"given":"Masayoshi","family":"Otsu","sequence":"first","affiliation":[{"name":"Kyoto University , , 46-29 Yoshida Shimoadachi-cho, Sakyo-ku , ,","place":["Kyoto, Japan, 606-8501"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9070-3575","authenticated-orcid":true,"given":"Kosuke","family":"Saito","sequence":"additional","affiliation":[{"name":"Kyoto University , , 46-29 Yoshida Shimoadachi-cho, Sakyo-ku , ,","place":["Kyoto, Japan, 606-8501"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3462-7354","authenticated-orcid":true,"given":"Kazuma","family":"Nakashima","sequence":"additional","affiliation":[{"name":"Kyoto University , , 46-29 Yoshida Shimoadachi-cho, Sakyo-ku , ,","place":["Kyoto, Japan, 606-8501"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Fujimoto","sequence":"additional","affiliation":[{"name":"Kyoto University , , Yoshida Konoe-cho, Sakyo-ku , ,","place":["Kyoto, Japan, 606-8501"]},{"name":"Kyoto University , , 46-29 Yoshida Shimoadachi-cho, Sakyo-ku , ,","place":["Kyoto, Japan, 606-8501"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7936-2263","authenticated-orcid":true,"given":"Masashi","family":"Murakami","sequence":"additional","affiliation":[{"name":"The University of Osaka , , Machikaneyama-cho, Toyonaka-shi , ,","place":["Osaka, Japan, 560-0043"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Ooe","sequence":"additional","affiliation":[{"name":"The University of Osaka , , Machikaneyama-cho, Toyonaka-shi , ,","place":["Osaka, Japan, 560-0043"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Toyoshima","sequence":"additional","affiliation":[{"name":"The University of Osaka , , Machikaneyama-cho, Toyonaka-shi , ,","place":["Osaka, Japan, 560-0043"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8873-1224","authenticated-orcid":true,"given":"Hiroyuki","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Kyoto University , , 46-29 Yoshida Shimoadachi-cho, Sakyo-ku , ,","place":["Kyoto, Japan, 606-8501"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2497-039X","authenticated-orcid":true,"given":"Masahiro","family":"Ono","sequence":"additional","affiliation":[{"name":"Kyoto University , , 46-29 Yoshida Shimoadachi-cho, Sakyo-ku , ,","place":["Kyoto, Japan, 606-8501"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"key":"2026102305081484500_cit1","doi-asserted-by":"publisher","first-page":"184","DOI":"10.3389\/fendo.2012.00184","article-title":"Neurotensin and its high affinity receptor 1 as a potential pharmacological target in cancer therapy","volume":"3","author":"Wu","year":"2012","journal-title":"Front. Endocrinol."},{"issue":"3","key":"2026102305081484500_cit2","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/labinvest.2014.165","article-title":"The potential of neurotensin secreted from neuroendocrine tumor cells to promote gelsolin-mediated invasiveness of prostate adenocarcinoma cells","volume":"95","author":"Hashimoto","year":"2015","journal-title":"Lab. Invest."},{"issue":"7","key":"2026102305081484500_cit3","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.3390\/ijms20071721","article-title":"Neurotensin receptor-1 expression in human prostate cancer: a pilot study on primary tumors and lymph node metastases","volume":"20","author":"Morgat","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"2026102305081484500_cit4","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1002\/1878-0261.12815","article-title":"Neurotensin receptor 1 signaling promotes pancreatic cancer progression","volume":"15","author":"Takahashi","year":"2021","journal-title":"Mol. Oncol."},{"issue":"2","key":"2026102305081484500_cit5","doi-asserted-by":"publisher","first-page":"448","DOI":"10.62347\/UAKN9541","article-title":"Neuron-derived neurotensin promotes pancreatic cancer invasiveness and gemcitabine resistance via the NTSR1\/Akt pathway","volume":"14","author":"Hung","year":"2024","journal-title":"Am. J. Cancer Res."},{"key":"2026102305081484500_cit6","doi-asserted-by":"publisher","first-page":"111877","DOI":"10.1016\/j.mrfmmm.2024.111877","article-title":"NTSR1 promotes epithelial-mesenchymal transition and metastasis in lung adenocarcinoma through the Wnt\/beta-catenin pathway","volume":"829","author":"Zhang","year":"2024","journal-title":"Mutat. Res."},{"issue":"15","key":"2026102305081484500_cit7","doi-asserted-by":"publisher","first-page":"3403","DOI":"10.1021\/jm030081k","article-title":"Novel bioactive and stable neurotensin peptide analogues capable of delivering radiopharmaceuticals and molecular beacons to tumors","volume":"46","author":"Achilefu","year":"2003","journal-title":"J. Med. Chem."},{"issue":"10","key":"2026102305081484500_cit8","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1021\/acs.bioconjchem.0c00419","article-title":"Silicon-containing neurotensin analogues as radiopharmaceuticals for NTS1-positive tumors imaging","volume":"31","author":"Fanelli","year":"2020","journal-title":"Bioconjug. Chem."},{"issue":"3","key":"2026102305081484500_cit9","doi-asserted-by":"publisher","first-page":"310","DOI":"10.3390\/pharmaceutics17030310","article-title":"Reshaping [99mTc]Tc-DT11 to DT14D tagged with trivalent radiometals for NTS1R-positive cancer theranostics","volume":"17","author":"Kanellopoulos","year":"2025","journal-title":"Pharmaceutics"},{"issue":"2","key":"2026102305081484500_cit10","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/s0022-3565(24)36482-1","article-title":"Biochemical and pharmacological activities of SR 142948A, a new potent neurotensin receptor antagonist","volume":"280","author":"Gully","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"22","key":"2026102305081484500_cit11","doi-asserted-by":"publisher","first-page":"9361","DOI":"10.1021\/jm401491e","article-title":"Synthesis and evaluation of a 18F-labeled diarylpyrazole glycoconjugate for the imaging of NTS1-positive tumors","volume":"56","author":"Lang","year":"2013","journal-title":"J. Med. Chem."},{"issue":"3","key":"2026102305081484500_cit12","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1002\/jlcr.3581","article-title":"Radiopharmaceuticals for imaging and endoradiotherapy of neurotensin receptor-positive tumors","volume":"61","author":"Maschauer","year":"2018","journal-title":"J. Labelled Comp. Radiopharm."},{"issue":"12","key":"2026102305081484500_cit13","doi-asserted-by":"publisher","first-page":"8564","DOI":"10.1021\/acs.jmedchem.1c00523","article-title":"Positron emission tomography imaging of neurotensin receptor-positive tumors with 68Ga-labeled antagonists: the chelate makes the difference again","volume":"64","author":"Renard","year":"2021","journal-title":"J. Med. Chem."},{"issue":"6","key":"2026102305081484500_cit14","doi-asserted-by":"publisher","first-page":"936","DOI":"10.2967\/jnumed.116.185140","article-title":"Proof of therapeutic efficacy of a 177Lu-labeled neurotensin receptor 1 antagonist in a colon carcinoma xenograft model","volume":"58","author":"Schulz","year":"2017","journal-title":"J. Nucl. Med."},{"issue":"5","key":"2026102305081484500_cit15","doi-asserted-by":"publisher","first-page":"809","DOI":"10.2967\/jnumed.117.193847","article-title":"177Lu-3BP-227 for neurotensin receptor 1-targeted therapy of metastatic pancreatic adenocarcinoma: first clinical results","volume":"59","author":"Baum","year":"2018","journal-title":"J. Nucl. Med."},{"key":"2026102305081484500_cit16","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.critrevonc.2018.01.001","article-title":"Global comparison of targeted alpha vs targeted beta therapy for cancer: in vitro, in vivo and clinical trials","volume":"123","author":"Marcu","year":"2018","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"1","key":"2026102305081484500_cit17","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3390\/pharmaceutics13010049","article-title":"Targeted alpha therapy: progress in radionuclide production, radiochemistry, and applications","volume":"13","author":"Nelson","year":"2020","journal-title":"Pharmaceutics"},{"issue":"8","key":"2026102305081484500_cit18","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.3390\/ph18081215","article-title":"Targeted alpha therapy: exploring the clinical insights into [225Ac]Ac-PSMA and its relevance compared with [177Lu]Lu-PSMA in advanced prostate cancer management","volume":"18","author":"Jalloul","year":"2025","journal-title":"Pharmaceuticals"},{"issue":"1","key":"2026102305081484500_cit19","doi-asserted-by":"publisher","first-page":"76","DOI":"10.3390\/ph17010076","article-title":"Alpha-emitting radionuclides: current status and future perspectives","volume":"17","author":"Miederer","year":"2024","journal-title":"Pharmaceuticals"},{"issue":"5","key":"2026102305081484500_cit20","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s44211-024-00514-w","article-title":"Recent advances in the development of 225Ac- and 211At-labeled radioligands for radiotheranostics","volume":"40","author":"Munekane","year":"2024","journal-title":"Anal. Sci."},{"issue":"1","key":"2026102305081484500_cit21","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s41181-024-00298-4","article-title":"Astatine-211 radiolabelling chemistry: from basics to advanced biological applications","volume":"9","author":"Vanermen","year":"2024","journal-title":"EJNMMI Radiopharm. Chem"},{"key":"2026102305081484500_cit22","doi-asserted-by":"publisher","first-page":"1076210","DOI":"10.3389\/fmed.2022.1076210","article-title":"Astatine-211 based radionuclide therapy: current clinical trial landscape","volume":"9","author":"Albertsson","year":"2023","journal-title":"Front. Med."},{"issue":"11","key":"2026102305081484500_cit23","doi-asserted-by":"publisher","first-page":"5543","DOI":"10.1021\/acs.molpharmaceut.3c00427","article-title":"Effective treatment of SSTR2-positive small cell lung cancer using 211At-containing targeted \u03b1-particle therapy agent which promotes endogenous antitumor immune response","volume":"20","author":"Qin","year":"2023","journal-title":"Mol. Pharm."},{"issue":"3","key":"2026102305081484500_cit24","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s00259-022-06016-z","article-title":"Targeted \u03b1-therapy using astatine (211At)-labeled PSMA1, 5, and 6: a preclinical evaluation as a novel compound","volume":"50","author":"Watabe","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"6","key":"2026102305081484500_cit25","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1007\/s00259-024-07056-3","article-title":"An 211At-labeled alpha-melanocyte stimulating hormone peptide analog for targeted alpha therapy of metastatic melanoma","volume":"52","author":"Suzuki","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"9","key":"2026102305081484500_cit26","doi-asserted-by":"publisher","first-page":"3553","DOI":"10.1021\/acs.molpharmaceut.1c00460","article-title":"68Ga- and 211At-labeled RGD peptides for radiotheranostics with multiradionuclides","volume":"18","author":"Ogawa","year":"2021","journal-title":"Mol. Pharm."},{"issue":"2","key":"2026102305081484500_cit27","doi-asserted-by":"publisher","first-page":"259","DOI":"10.2967\/jnumed.121.262098","article-title":"An improved 211At-labeled agent for PSMA-targeted \u03b1-therapy","volume":"63","author":"Mease","year":"2022","journal-title":"J. Nucl. Med."},{"issue":"12","key":"2026102305081484500_cit28","doi-asserted-by":"publisher","first-page":"12940","DOI":"10.1021\/acs.jmedchem.5c00837","article-title":"Design, structure optimization, and preclinical evaluation of 188Re-labeled FAPI for targeted radionuclide therapy","volume":"68","author":"Xu","year":"2025","journal-title":"J. Med. Chem."},{"issue":"6","key":"2026102305081484500_cit29","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.3390\/cancers15061889","article-title":"Novel generation of FAP inhibitor-based homodimers for improved application in radiotheranostics","volume":"15","author":"Martin","year":"2023","journal-title":"Cancers"},{"issue":"7","key":"2026102305081484500_cit30","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1021\/acs.bioconjchem.2c00214","article-title":"Examination of charge modifications of an endolysosomal trapping inhibitor in an antagonistic NTSR1-targeted construct for colon cancer","volume":"33","author":"Fan","year":"2022","journal-title":"Bioconjug. Chem."},{"issue":"1\u22122","key":"2026102305081484500_cit31","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/0014-5793(93)81509-X","article-title":"Cloning and expression of a complementary-DNA encoding a high-affinity human neurotensin receptor","volume":"317","author":"Vita","year":"1993","journal-title":"FEBS Lett."},{"issue":"9","key":"2026102305081484500_cit32","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1021\/bc800157h","article-title":"Synthesis, 18F-labeling, and in vitro and in vivo studies of bombesin peptides modified with silicon-based building blocks","volume":"19","author":"Hohne","year":"2008","journal-title":"Bioconjug. Chem."},{"issue":"12","key":"2026102305081484500_cit33","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1021\/bc100316c","article-title":"One-step 18F-labeling of carbohydrate-conjugated octreotate-derivatives containing a silicon-fluoride-acceptor (SiFA): in vitro and in vivo evaluation as tumor imaging agents for positron emission tomography (PET)","volume":"21","author":"Wa\u0308ngler","year":"2010","journal-title":"Bioconjug. Chem."},{"issue":"9","key":"2026102305081484500_cit34","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.2967\/jnumed.116.188722","article-title":"Dual-target binding ligands with modulated pharmacokinetics for endoradiotherapy of prostate cancer","volume":"58","author":"Kelly","year":"2017","journal-title":"J. Nucl. Med."},{"issue":"6","key":"2026102305081484500_cit35","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1021\/acs.molpharmaceut.8b00152","article-title":"Preclinical development of novel PSMA-targeting radioligands: modulation of albumin-binding properties to improve prostate cancer therapy","volume":"15","author":"Umbricht","year":"2018","journal-title":"Mol. Pharm."},{"issue":"6","key":"2026102305081484500_cit36","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/s0026-895x(25)10691-3","article-title":"The characterization of two specific drug binding sites on human serum albumin","volume":"11","author":"Sudlow","year":"1975","journal-title":"Mol. Pharmacol."},{"key":"2026102305081484500_cit37","doi-asserted-by":"publisher","first-page":"116888","DOI":"10.1016\/j.molliq.2021.116888","article-title":"Probing the interaction of memantine, an important Alzheimer\u2019s drug, with human serum albumin: In silico and in vitro approach","volume":"340","author":"Alhumaydhi","year":"2021","journal-title":"J. Mol. Liq."},{"issue":"9","key":"2026102305081484500_cit38","doi-asserted-by":"publisher","first-page":"2500011","DOI":"10.1002\/anbr.202500011","article-title":"Advances on albumin-based carriers for anticancer drug delivery","volume":"5","author":"Zhou","year":"2025","journal-title":"Adv. NanoBiomed Res."},{"issue":"17","key":"2026102305081484500_cit39","doi-asserted-by":"publisher","first-page":"3196","DOI":"10.1002\/anie.200704936","article-title":"A portable albumin binder from a DNA-encoded chemical library","volume":"47","author":"Dumelin","year":"2008","journal-title":"Angew. Chem. Int. Ed."},{"key":"2026102305081484500_cit40","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.bbrep.2018.01.006","article-title":"Crystal structure analysis of human serum albumin complexed with sodium 4-phenylbutyrate","volume":"13","author":"Kawai","year":"2018","journal-title":"Biochem. Biophys. Rep."},{"issue":"5","key":"2026102305081484500_cit41","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1021\/acs.molpharmaceut.4c00044","article-title":"Role for carboxylic acid moiety in NSAIDs: favoring the binding at site II of bovine serum albumin","volume":"21","author":"de Carvalho Bertozo","year":"2024","journal-title":"Mol. Pharm."},{"issue":"7","key":"2026102305081484500_cit42","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.7150\/thno.18719","article-title":"177Lu-labeled phosphoramidate-based PSMA inhibitors: the effect of an albumin binder on biodistribution and therapeutic efficacy in prostate tumor-bearing mice","volume":"7","author":"Choy","year":"2017","journal-title":"Theranostics"},{"issue":"18","key":"2026102305081484500_cit43","doi-asserted-by":"publisher","first-page":"10655","DOI":"10.3390\/ijms231810655","article-title":"Oxidation of p-[125I]iodobenzoic acid and p-[211At]astatobenzoic acid derivatives and evaluation in vivo","volume":"23","author":"Li","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"2026102305081484500_cit44","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1039\/d3md00579h","article-title":"In vivo stability of 211At-radiopharmaceuticals: on the impact of halogen bond formation","volume":"15","author":"Yssartier","year":"2024","journal-title":"RSC Med. Chem."},{"issue":"21","key":"2026102305081484500_cit45","doi-asserted-by":"publisher","first-page":"7512","DOI":"10.1021\/jo971176v","article-title":"NMR chemical shifts of common laboratory solvents as trace impurities","volume":"62","author":"Gottlieb","year":"1997","journal-title":"J. Org. Chem."},{"key":"2026102305081484500_cit46","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.nucmedbio.2021.05.007","article-title":"Production, purification and availability of 211At: near term steps towards global access","volume":"100\u2212101","author":"Feng","year":"2021","journal-title":"Nucl. Med. Biol."},{"issue":"16","key":"2026102305081484500_cit47","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1021\/jm00042a014","article-title":"Maleimidoethyl 3-(tri-n-butylstannyl)hippurate: a useful radioiodination reagent for protein radiopharmaceuticals to enhance target selective radioactivity localization","volume":"37","author":"Arano","year":"1994","journal-title":"J. Med. Chem."},{"key":"2026102305081484500_cit48","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.isci.2019.08.021","article-title":"Synthesis of biaryls via decarbonylative palladium-catalyzed suzuki-miyaura cross-coupling of carboxylic acids","volume":"19","author":"Liu","year":"2019","journal-title":"iScience"},{"issue":"7","key":"2026102305081484500_cit49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0022418","article-title":"Synthesis and investigation of a radioiodinated F3 peptide analog as a SPECT tumor imaging radioligand","volume":"6","author":"Bhojani","year":"2011","journal-title":"PLoS One"},{"issue":"8","key":"2026102305081484500_cit50","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/jlcr.4112","article-title":"Synthesis and evaluation of a cathepsin B-recognizing trifunctional chelating agent to improve tumor retention of radioimmunoconjugates","volume":"67","author":"Jinda","year":"2024","journal-title":"J. Labelled Comp. Radiopharm."},{"issue":"7","key":"2026102305081484500_cit51","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.2967\/jnumed.115.170530","article-title":"Comparative evaluation of the biodistribution profiles of a series of nonpeptidic neurotensin receptor-1 antagonists reveals a promising candidate for theranostic applications","volume":"57","author":"Schulz","year":"2016","journal-title":"J. Nucl. Med."}],"container-title":["Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.jmedchem.6c00852","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/69\/20\/23585\/68646668\/jm6c00852.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/69\/20\/23585\/68646668\/jm6c00852.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T09:29:14Z","timestamp":1792747754000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article\/69\/20\/23585\/5438135\/Development-of-Novel-211At-Labeled-Agent-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":51,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2026,9,25]]},"published-print":{"date-parts":[[2026,10,22]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.jmedchem.6c00852","relation":{},"ISSN":["0022-2623","1520-4804"],"issn-type":[{"value":"0022-2623","type":"print"},{"value":"1520-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]}}}